CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits (Q37012022)

17 August 2017

1 reference

title

CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits (English)

1 reference

17 August 2017

0 references

Pedro Dorado

1

0 references

author name string

Eva M Peñas-Lledó

series ordinal

2

1 reference

PubMed ID

18034624

17 August 2017

Adrián Llerena

series ordinal

3

1 reference

PubMed ID

18034624

17 August 2017

Adrián Llerena

series ordinal

4

1 reference

17 August 2017

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

11

1 reference

17 August 2017

1597-1608

1 reference

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.

17 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Schizophrenia and tobacco smoking in a Spanish psychiatric hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Markers for vulnerability to psychopathology: temperament traits associated with platelet MAO activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Relationship between Type A and B personality and debrisoquine hydroxylation capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Association between cytochrome P450 2D6 genotype and harm avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Dopamine formation from tyramine by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

[3H]WAYâ 100635 for 5â HT1A receptor autoradiography in human brain: a comparison with [3H]8â OHâ DPAT and demonstration of increased binding in the frontal cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Pharmacogenetics of classical and new antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Lack of association between schizophrenia and theCYPZD6 gene polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

DEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Relationship between personality and debrisoquine hydroxylation capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

The Underlying Traits of the Karolinska Scales of Personality (KSP)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Use of the Mesoridazine/Thioridazine Ratio as a Marker for CYP2D6 Enzyme Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1597

10.2217/14622416.8.11.1597

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18034624